Phase 3 N=635 Relapse Prevention Study in Patients With Schizophrenia
Schizophrenia
Primary: Time to Relapse or Impending Relapse — NA; 99 Days — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=145 A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.
Generalized Myasthenia Gravis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious AEs, TEAEs Leading to Study Drug Discontinuation and Fatal TEAE in…
Phase 3 N=1,323 COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)
Covid19 · SARS-CoV Infection
Primary: Clinical Progression to Severe Covid — 154; 179; 105; 96 Participants
Phase 3 N=730 An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)
Coronary Artery Disease (CAD)
Primary: Sensitivity and Specificity of Flurpiridaz (18F) Injection Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) in the Detection of Significant Coronary…
Phase 3 N=220 Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair
Peripheral Nerve Discontinuities
Primary: Static Two-Point Discrimination (Pre-defined Mixed Modeling Approach) — 9.1; 9.3 Millimeters
Phase 3 N=81 Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID
Primary Immunodeficiency Disease
Primary: Rate of Acute Serious Bacterial Infections — 0.015 SBI rate per subject-year
Phase 3 N=320 EVarQuit: Extended Pre-quit Varenicline to Assist in Quitting Smoking
Tobacco Smoking
Primary: Number of Participants With Continuous Abstinence at End-of-Treatment (EOT) as Assessed by Self-Report and Bio-verification — 64; 57 Participants
Phase 3 N=6,263 Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
Heart Failure With Preserved Ejection Fraction
Primary: Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure. — 512; 610 Participants — p=0.0008
Phase 3 N=452 Long-term Study of Efficacy/Safety of Adapalene/Benzoyl Peroxide Topical Gel in Acne Vulgaris Subjects
Acne Vulgaris
Primary: Percent Change From Baseline in Inflammatory, Noninflammatory and Total Lesion Count at Month 12 LOCF — -59.70; -58.80; -58.85 percent change
Phase 3 N=288 Maintenance Effect of Clobex Shampoo on Participants With Moderate to Severe Scalp Psoriasis
Scalp Psoriasis
Primary: Maintenance Phase: Time to First Relapse — 93.5; 56.8 days
Phase 3 N=86 A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)
Cystic Fibrosis
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 61; 4 Participants
Phase 3 N=194 Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial
Uveitis · Macular Edema
Primary: Proportion of Baseline Central Subfield Thickness Observed at 12 Weeks — 0.65; 0.88; 0.79 Proportion of baseline retinal thickness — p=<0.001
Phase 3 N=137 Chlorhexidine vs. Iodine for Vaginal Preparation in Urogynecologic Procedures
Pelvic Organ Prolapse · Urinary Incontinence · Pelvic Floor Disorders
Primary: Rate of Urinary Tract Infection — 4; 7 Participants
Phase 3 N=370 Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study
Ocular Inflammation and Pain After Cataract Surgery
Primary: Participants With ACC Count = 0 in the Operated Study Eye at All Visits From Postoperative Day 8 Through Postoperative Day 15 Without Rescue Medication — 49; 16…
Phase 3 N=34 Comparative Effectiveness of Two Acellular Matrices (Dermacell vs. Integra) for Management of Deep Diabetic Foot Ulcers
Diabetic Foot Ulcer · Deep Diabetic Foot Ulcer
Primary: Wound Area at 16 Weeks — 6.1; 6.8 cm^2